Obtaining prefrontal cortex biopsies during deep brain stimulation adds no risk to procedure

Notice: News releases are not subject to review by MedLink Neurology’s Editorial Board.

Obtaining prefrontal cortex biopsies during deep brain stimulation surgery in living patients does not increase the risk of adverse events or cognitive decline compared to standard deep brain stimulation procedures that don’t involve biopsies, a team of clinical research scientists at the Icahn School of Medicine at Mount Sinai has demonstrated.

The study findings, published online September 3 in Neurosurgery, the official publication of the Congress of Neurological Surgeons, establish the safety of an approach that allows researchers to collect valuable living human brain tissue during planned neurosurgical procedures, addressing a critical barrier in neuroscience research while maintaining patient safety. Most studies of how the brain works at the molecular level have been performed using samples from deceased patients because of the lack of safe approaches to sampling the living human brain.

“Through the Living Brain Project at Mount Sinai, we developed a method to safely biopsy a small volume of brain tissue from a region of the prefrontal cortex during placement of the deep brain stimulation lead,” said Brian Kopell MD, Director of the Center for Neuromodulation, co-lead of the Living Brain Project at Mount Sinai, and co-senior author of the paper. “The retrospective safety analysis clearly demonstrates that there are safe and innovative ways of involving neurosurgical patients in research activities that have the potential to greatly advance science. We extend our deepest gratitude to the patients who have chosen to partner with us on this work.”

The research team analyzed acute adverse events, defined as infection, intracranial hemorrhage, and seizures, following 1,152 deep brain stimulation lead placements performed on 590 patients at a single hospital between 2013 and 2024. Prefrontal cortex biopsies were obtained in 652 procedures (“biopsy group”) and not obtained in 500 procedures (“non-biopsy group”). A CT scan was performed within hours of each procedure, and patient medical records were reviewed for acute intracranial hemorrhage, seizure, and infection from the procedure date to 90 days later. A subset of patients was followed for approximately one year to assess cognitive outcomes.

No infections occurred in either group. No statistically significant differences in intracranial hemorrhage rate or seizure rate were observed between groups (intracranial hemorrhage rate: 1.7% biopsy group vs. 1.4% non-biopsy group; chi-square test p-value=0.88; seizure rate: 0.2% biopsy group vs. 0.4% non-biopsy group; p-value=0.82). No statistically significant associations were observed between number of biopsies and changes in cognitive health over time.

Deep brain stimulation is an elective neurosurgical treatment for neurological and mental health illnesses. A common technique for safely implanting the deep brain stimulation electrode involves cauterizing a small volume of prefrontal cortex prior to inserting the cannula, a specialized hollow tube through which the electrode lead is placed. For the current study, all deep brain stimulation procedures were performed by a single neurosurgeon using standard stereotactic techniques. All procedures involved a standard frontal burr hole and stereotactic cannula placement, with cortical surface preparation differing only by the inclusion of a prefrontal cortex biopsy (obtained prior to cauterization and using a standard punch tool). Biopsy sizes were measured for 231 biopsies. The mean biopsy volume measured was equal to 40mm³ and the median volume was equal to 30mm³. The study authors note that the tight biopsy sizes distributed around the mean demonstrate that the Living Brain Project prefrontal cortex biopsy procedure can be highly standardized, reproducible, and precise.

“The ability to safely study the brain from people who are alive opens up a new world of questions about brain function that researchers can tackle,” said Alexander W Charney MD, PhD, Director of The Charles Bronfman Institute for Personalized Medicine, co-lead of the Living Brain Project, and co-senior author of the study. “By using this technique, the Living Brain Project is already making several contributions to medical research, including a comprehensive characterization of living human brain biology, technology to study human brain circuits at the synapse level, technology to deliver gene therapy to the brain, and insights into the pathogenesis of brain disease. Given the safety profile of the technique, we are eager for other institutions to follow the same methods and expand the scope of this work.”

Source: News Release
The Mount Sinai Hospital / Mount Sinai School of Medicine
September 3, 2025